Innoviva Bolsters Its Infectious Disease, Hospital Portfolio With La Jolla Deal

Innoviva Inc  (NASDAQ: INVA ) has agreed to acquire  La Jolla Pharmaceutical Company  (NASDAQ: LJPC ) for $5.95 per share, representing a premium of approximately 70% to the 30-day volume-weighted average price. Innoviva will also pay an incremental $0.28 per share for additional cash proceeds ... Full story available on